Advanced searches left 3/3

Metastatic Prostate Cancer Biopsy - Wiley Online Library

Summarized by Plex Scholar
Last Updated: 27 January 2022

* If you want to update the article please login/register

Combining liquid biopsy and functional imaging analysis in metastatic castrationā€resistant prostate cancer helps predict treatment outcome

Plasma tumour DNA analysis shows a potential early noninvasive biomarker of disease in metastatic castration-resistant prostate cancer. We looked at whether pre-treatment ptDNA levels reveal metabolic tumour burden in mCRPC and help anticipate treatment outcomes in combination with functional imaging. Targeted next-generation sequencing was used to determine the ptDNA percentage from 102 mCRPC patients receiving abiraterone or enzalutamide. Multiple independent predictors of both OS and PFS were found in the training set, multivariable studies revealed that ptDNA, MTV, and serum lactate dehydrogenase as well as visceral metastasis were reliable predictors of both OS and PFS. Prognostic scores were established, with the identification of three groups of patients with significantly different median OS and PFS probabilities. In the validation cohort for both OS and PFS, there were discrepancies in median survival among risk groups. In our study, we found that combining plasma DNA analysis with functional imaging could increase prognostic risk stratification and treatment selection in mCRPC.

Source link: https://onlinelibrary.wiley.com/doi/10.1002/1878-0261.13120

* Please keep in mind that all text is summarized by machine, we do not bear any responsibility, and you should always check original source before taking any actions

* Please keep in mind that all text is summarized by machine, we do not bear any responsibility, and you should always check original source before taking any actions